221322-07-2

Basic information

• Product Name: 2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID
• Synonyms: 2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID;2-((Pivaloyloxy)methyl)thiazole-4-carboxylic acid
• CAS NO: 221322-07-2
• Molecular Formula: C₁₀H₁₃NO₄S
• Molecular Weight: 243.28
• Mol File: 221322-07-2.mol

Chemical Properties

• Boiling Point: 380.791 °C at 760 mmHg
• Flash Point: 184.096 °C
• Appearance: /
• Density: 1.301 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID(221322-07-2)
• EPA Substance Registry System: 2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID(221322-07-2)

Safety Data

• Hazardous Substances Data: 221322-07-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID is used as an antimicrobial agent for its potential antibacterial and antifungal properties. The thiazole ring structure in the compound is known to contribute to its effectiveness against various microorganisms.
Used in Drug Development:
2-(2,2-DIMETHYL-PROPIONYLOXYMETHYL)-THIAZOLE-4-CARBOXYLIC ACID is used as a promising candidate for drug development due to its enhanced stability and lipophilicity provided by the 2,2-dimethyl group. This makes the compound more suitable for formulation and delivery in pharmaceutical applications.
Further research and testing are required to fully determine the potential uses and benefits of 2-(2,2-dimethyl-propionyloxymethyl)-thiazole-4-carboxylic acid in various applications.

InChI:InChI=1/C10H13NO4S/c1-10(2,3)9(14)15-4-7-11-6(5-16-7)8(12)13/h5H,4H2,1-3H3,(H,12,13)

Upstream product

• 1113-59-3 bromopyruvic acid 
• 175204-79-2 2,2-dimethyl-propionic acid thiocarbamoylmethyl ester 

Downstream Products

• 1198802-99-1 N-{6-bromo-1-[(4-methylphenyl)sulfonyl]-1H-indazol-4-yl}-2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-thiazole-4-carboxamide 
• 1198802-98-0 N-{6-bromo-1-[(4-methylphenyl)sulfonyl]-1H-indazol-4-yl}-2-(chloromethyl)-1,3-thiazole-4-carboxamide 
• 1198802-87-7 2-(chloromethyl)-N-[6-{6-(methyloxy)-5-[(methylsulfonyl)amino]-3-pyridinyl}-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide 
• 1198438-12-8 2-(chloromethyl)-N-{1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-indazol-4-yl}-1,3-thiazole-4-carboxamide 
• 1198437-95-4 2-(chloromethyl)-N-[6-(1H-indol-4-yl)-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide 
• 1198803-49-4 2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-N-{6-[6-(methyloxy)-5-({[2-(methyloxy)phenyl]sulfonyl}amino)-3-pyridinyl]-1H-indazol-4-yl}-1,3-thiazole-4-carboxamide trifluoroacetate 
• 1198803-00-7 N-{6-[5-{[(2,4-difluorophenyl)sulfonyl]amino}-6-(methyloxy)-3-pyridinyl]-1-[(4-methylphenyl)sulfonyl]-1H-indazol-4-yl}-2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-thiazole-4-carboxamide 
• 1198803-79-0 N-{6-[5-{[(2,4-difluorophenyl)sulfonyl]amino}-6-(methyloxy)-3-pyridinyl]-1H-indazol-4-yl}-2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-thiazole-4-carboxamide 
• 1198803-85-8 N-{6-[5-{[(2,4-difluorophenyl)sulfonyl]amino}-6-(methyloxy)-3-pyridinyl]-1-methyl-1H-indazol-4-yl}-2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-thiazole-4-carboxamide 
• 1198803-04-1 N-{6-[5-amino-6-(methyloxy)-3-pyridinyl]-1-[(4-methylphenyl)sulfonyl]-1H-indazol-4-yl}-2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-thiazole-4-carboxamide 
• 1198802-85-5 2-(chloromethyl)-N-[6-{6-chloro-5-[(methylsulfonyl)amino]-3-pyridinyl}-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide 
• 1198438-27-5 2-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-N-{1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1H-indazol-4-yl}-1,3-thiazole-4-carboxamide 
• 1198438-19-5 2-(chloromethyl)-N-{1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1H-indazol-4-yl}-1,3-thiazole-4-carboxamide 

Relevant articles and documents

Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists

A series of small molecules consisting of a heterocyclic core flanked by two basic functionalities were synthesized and screened for in vitro affinity at the human histamine H3 receptor (hH3R). Nine of the twenty-eight compounds tested were found to possess a hH3R Ki of less than 5 nM and consisted of a diverse range of central hetero-aromatic linkers (pyridine, pyrazine, oxazole, isoxazole, thiazole, furan, thiophene, and pyrrole). One member of this series, (4-isopropyl-piperazin-1-yl)-(6-piperidin-1-ylmethyl-pyridin-3-yl)-methanone (37), was found to be a high affinity, selective antagonist that crosses the blood-brain barrier and occupies H3 receptors after oral administration in the rat.

Non-imidazole heterocyclic compounds

Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.

N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151)

Described herein is a modern approach to the rapid preparation and evaluation of compounds as potential back-up drug candidates. GW311616A, 1, a derivative of pyrrolidine trans-lactams, has previously been described as a potent, orally active inhibitor of